Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Biotechnology Assets's annualized net income for the quarter that ended in Dec. 2025 was €-2.16 Mil. Biotechnology Assets's average shareholder tangible equity for the quarter that ended in Dec. 2025 was €0.00 Mil. Therefore, Biotechnology Assets's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was N/A%.
The historical rank and industry rank for Biotechnology Assets's Return-on-Tangible-Equity or its related term are showing as below:
STU:041'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -1011.09 Med: -176.37 Max: -85.83
Current: -106.98
During the past 13 years, Biotechnology Assets's highest Return-on-Tangible-Equity was -85.83%. The lowest was -1,011.09%. And the median was -176.37%.
STU:041's Return-on-Tangible-Equity is ranked worse than 74.5% of 1204
companies
in the Biotechnology industry
Industry Median: -42.15
vs STU:041: -106.98
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Biotechnology Assets Return-on-Tangible-Equity Related Terms
Biotechnology Assets Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Biotechnology Assets's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:041 vs VRTX, REGN, MRNA: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Biotechnology Assets's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biotechnology Assets Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Biotechnology Assets's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Biotechnology Assets's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -153.90% mean?
Biotechnology Assets (STU:041) has a Return-on-Tangible-Equity of -153.90% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Biotechnology Assets and its competitors. According to the industry distribution chart, Biotechnology Assets ranks #897 out of 1204 companies in the Biotechnology industry, placing it in the top 74.5%.
Is Biotechnology Assets' Return-on-Tangible-Equity too high?
Biotechnology Assets' current Return-on-Tangible-Equity is -153.90%. Based on the distribution chart, Biotechnology Assets ranks #897 out of 1204 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Biotechnology Assets has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Biotechnology Assets' Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Biotechnology Assets ranks #897 out of 1204 companies for Return-on-Tangible-Equity. This places Biotechnology Assets in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Biotechnology Assets and its competitors. Biotechnology Assets's current Return-on-Tangible-Equity is -153.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotechnology Assets stock overvalued right now?
Biotechnology Assets (STU:041) has a current Return-on-Tangible-Equity of -153.90%. The stock's GF Value™ is €0.32, compared to a current price of €0.25 — trading 20.9% below its estimated fair value. The current Return-on-Tangible-Equity is -153.90%. Biotechnology Assets' overall GF Score™ is 19/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Biotechnology Assets (STU:041), the current Return-on-Tangible-Equity is -153.90% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biotechnology Assets (STU:041) Overvalued in 2026?
Based on GuruFocus' analysis, Biotechnology Assets stock appears to be undervalued.
The current stock price of €0.25 is trading 20.9% below its estimated GF Value™ of €0.32.
Key valuation signals for STU:041:
Return-on-Tangible-Equity: -153.90%
GF Value™: €0.32 vs. price of €0.25 (20.9% below fair value)
No single metric tells the full story. See the STU:041 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADL Bionatur Solutions SA is a Spanish biopharmaceutical company focused on the research, development, and manufacture of biological products for the pharmaceutical and animal health sectors. It specializes in fermentation-based biotechnological processes and produces ingredients such as probiotics, feed additives, antigens for vaccines, and other biological compounds. Its customers include animal health and pharmaceutical companies, to which it supplies both therapeutic and non-therapeutic products, as well as contract manufacturing and development services. The company operates through segments covering animal health and human health, with production facilities in Spain and commercial activity across Europe and other international markets. Revenue is generated primarily from product sales and contract manufacturing agreements with tier-one and tier-two animal health firms. Its development pipeline includes vaccine antigens and biological candidates targeting niche and orphan diseases.
19GF Score
Get the complete analysis for STU:041
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:041 has been successfully added to your 
